Targeted inactivation of EPS8 using dendrimer-mediated delivery of RNA interference

Quan Yuan, William Andrew Yeudall, Eunmee Lee, Hu Yang

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


We developed polyamidoamine dendrimers conjugated with epidermal growth factor (EGF) for use in receptor-mediated delivery of therapeutics to cancer cells. Here, we demonstrate the utility of this approach to inhibit proliferation and migration of head and neck squamous carcinoma cells through targeting of EPS8, a key regulator of squamous carcinoma growth and motility. Use of EGF-dendrimers to deliver siRNA or shRNA against EPS8 resulted in inhibition of cell growth and reduction in cell motility. Moreover, more profound repression of the target protein was obtained with repeat exposure to the targeting reagent, and was consistent with the altered biological properties. Thus, targeting of EPS8 can be achieved with EGF-conjugated dendrimers delivering EPS8-specific RNAi therapeutics, leading to a reduction in the malignant phenotype of cells.

Original languageEnglish (US)
Pages (from-to)178-181
Number of pages4
JournalInternational Journal of Pharmaceutics
StatePublished - Feb 25 2019


  • Dendrimer
  • EGFR
  • Oral cancer
  • Signal transduction
  • Targeted therapy

ASJC Scopus subject areas

  • Pharmaceutical Science


Dive into the research topics of 'Targeted inactivation of EPS8 using dendrimer-mediated delivery of RNA interference'. Together they form a unique fingerprint.

Cite this